arrow
Back
H

Howard Gurney

chang gung university

64H-index
456Paper Count
3.6WCitation Count
Published Papers 131
Publication Date
Avelumab first-line maintenance for advanced urothelial carcinoma: long-term outcomes from the JAVELIN Bladder 100 trial in patients with high body mass index or diabetes mellitus
err2026-06-12
err0
errOAAI
errJ.B. Aragon-Ching; S. Gupta; P. Grivas; S.H. Park; D.P. Petrylak; S.S. Sridhar; H. Gurney; N. Jacob; K. Tyroller; J. Hoffman; J. Bellmunt
errShare
errSave
Niraparib With Abiraterone Acetate Plus Prednisone as First-Line Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Repair Gene Alterations: Final Analysis of the Asian Subgroup From the MAGNITUDE Study
err2026-04-01
err1
PREAI
errYe, Dingwei; Saad, Marniza; Lee, Ji Youl; Jung, Wonho; Pang, See-Tong; Li, Lei; Gurney, Howard; Attard, Gerhardt; Chi, Kim N.; Mundle, Suneel; Zhuo, Jianmin; Singh, Anildeep; Lin, Yun; Sandhu, Shahneen
errShare
errSave
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis of efficacy and safety from the phase III CheckMate 214 trial☆
err2026-03-03
err0
errOAAI
errT.K. Choueiri; L. Albigès; D.F. McDermott; H.J. Hammers; B. Escudier; M. Burotto; E.R. Plimack; C. Porta; S. George; T. Powles; F. Donskov; M.B. Atkins; H. Gurney; C.K. Kollmannsberger; M.-O. Grimm; C. Barrios; D. Castellano; V. Grünwald; Y. Tomita; B.I. Rini
errShare
errSave
Pembrolizumab plus lenvatinib for previously untreated advanced non-clear cell renal cell carcinoma: 3-year follow-up of the phase 2 KEYNOTE-B61 study
err2025-10-01
err2
errOAAI
errAlbiges, Laurence; Gurney, Howard; Lee, Jae Lyun; Atduev, Vagif; Suarez, Cristina; Climent, Miguel A.; Pook, David; Tomczak, Piotr; Barthelemy, Philippe; Gedye, Craig; Lacombe, Louis; Ferguson, Thomas; Stus, Viktor; Wiechno, Pawel; Erman, Mustafa; Urun, Yuksel; Cornell, Jerry; Burgents, Joe; Sharma, Manish; Voss, Martin
errShare
errSave
Final analysis of nivolumab plus cabozantinib for advanced renal cell carcinoma from the randomized phase III CheckMate 9ER trial
err2025-09-23
err0
errOAAI
errR.J. Motzer; B. Escudier; M. Burotto; T. Powles; A.B. Apolo; M.T. Bourlon; A.Y. Shah; C. Porta; C. Suárez; C.H. Barrios; M. Richardet; H. Gurney; E.R. Kessler; Y. Tomita; J. Bedke; C. Scheffold; M. Askelson; J. Panzica; J. Zhang; M. van Kooten Losio; T.K. Choueiri
errShare
errSave
Psychosocial factors associated with perceived cognitive functioning in prostate cancer survivors: an exploratory cross-sectional analysis
err2025-08-02
err0
errOAAI
errLorna Pembroke; Kerry A. Sherman; Haryana M. Dhillon; Heather Francis; David Gillatt; Howard Gurney
errShare
errSave
First-line Pembrolizumab Plus Lenvatinib for Advanced Non–clear-cell Renal Cell Carcinoma: Updated Results from the Phase 2 KEYNOTE-B61 Trial
err2025-07-24
err0
PREAI
errMartin H. Voss; Howard Gurney; Vagif Atduev; Cristina Suarez; Miguel A. Climent; David Pook; Piotr Tomczak; Philippe Barthélémy; Jae Lyun Lee; Taron Nalbandian; Viktor Stus; Thomas Ferguson; Pawel Wiechno; Erhan Gokmen; Louis Lacombe; Craig Gedye; Jerry Cornell; Manish Sharma; Joseph E. Burgents; Laurence Albiges
errShare
errSave
Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Long-term Outcomes from the JAVELIN Bladder 100 Trial in Patients with Nonvisceral or Lymph Node–only Disease
err2025-06-03
err0
errOAAI
errJoaquim Bellmunt; Thomas Powles; Se Hoon Park; Eric Voog; Begona P. Valderrama; Howard Gurney; Anders Ullén; Yohann Loriot; Srikala S. Sridhar; Norihiko Tsuchiya; Cora N. Sternberg; Jeanny B. Aragon-Ching; Daniel P. Petrylak; Miguel A. Climent Duran; Karin Tyroller; Jason Hoffman; Natalia Jacob; Petros Grivas; Shilpa Gupta
errShare
errSave
Pembrolizumab plus enzalutamide versus placebo plus enzalutamide for chemotherapy-naive metastatic castration-resistant prostate cancer: the randomized, double-blind, phase III KEYNOTE-641 study☆
err2025-05-16
err0
PREAI
errJ.N. Graff; M. Burotto; P.C. Fong; D.W. Pook; B. Zurawski; R. Manneh Kopp; J. Salinas; K.A. Bylow; G. Kramer; R. Ratta; M. Kwiatkowski; M. Retz; C. Kwak; J.A. Arranz Arija; H. Gurney; N. Matsubara; L. Villanueva; T. Todenhöfer; L.W. Liang; J. Todoric; A. Stenzl
errShare
errSave
Patient-reported Outcomes in KEYNOTE-921: Pembrolizumab with Docetaxel and Prednisone for Patients with Metastatic Castration-resistant Prostate Cancer
err2025-05-13
err0
PREAI
errNobuaki Matsubara; Daniel Petrylak; Raffaele Ratta; Ernesto Korbenfeld; Rustem Gafanov; Loïc Mourey; Tilman Todenhöfer; Howard Gurney; Gero Kramer; Andries M. Bergman; Pawel Zalewski; Maria De Santis; Andrew J. Armstrong; Winald Gerritsen; Russell K. Pachynski; Todd L. Saretsky; Sameer R. Ghate; Fan Wang; Charles Schloss; Karim Fizazi
errShare
errSave
Niraparib and Abiraterone Acetate plus Prednisone in Metastatic Castration-resistant Prostate Cancer: Final Overall Survival Analysis for the Phase 3 MAGNITUDE Trial
err2025-05-05
err0
errOAAI
errKim N. Chi; Elena Castro; Gert Attard; Matthew R. Smith; Shahneen Sandhu; Eleni Efstathiou; Guilhem Roubaud; Eric J. Small; Andrea Pereira de Santana Gomes; Dana E. Rathkopf; Marniza Saad; Howard Gurney; Wonho Jung; Won Kim; Shiva Dibaj; Daphne Wu; Jenny Zhang; Angela Lopez-Gitlitz; Peter Francis; David Olmos
errShare
errSave
Phase 1 study of HP518, a PROTAC AR degrader in patients with mCRPC: results on safety, pharmacokinetics, and anti-tumor activity
err2025-04-28
err0
PREAI
errAzad, Arun A.; Gurney, Howard; Underhill, Craig; Horvath, Lisa; Voskoboynik, Mark; Li, Xinghai; King, Ivan; Shao, Lisa; Dai, Yiyun; Perabo, Frank
errShare
errSave
Avelumab first-line maintenance for advanced urothelial carcinoma: long-term outcomes from the JAVELIN Bladder 100 trial in older patients
err2025-04-01
err0
PREAI
errGupta, S.; Duran, M. A. Climent; Sridhar, S. S.; Powles, T.; Bellmunt, J.; Park, S. H.; Gurney, H.; Tsuchiya, N.; Petrylak, D. P.; Tomita, Y.; di Pietro, A.; Manitz, J.; Tyroller, K.; Hoffman, J.; Jacob, N.; Grivas, P.
errShare
errSave
Feasibility and population exposure of 5-fluorouracil using therapeutic drug monitoring (PREDICT-5FU): A multicentre clinical trial
err2025-02-23
err0
errOAAI
errGlewis, Sarah; Michael, Michael; Gurney, Howard; Olver, Ian; Zdenkowski, Nicholas; Ackland, Stephen; Kukard, Craig; Jayawardana, Madawa; Silva, S. Sandun M.; Alexander, Marliese; Tie, Jeanne; Galettis, Peter; Martin, Jennifer H.
errShare
errSave
Avelumab maintenance treatment for advanced urothelial cancer: plain language summary of long-term results from the JAVELIN Bladder 100 study
err2025-01-15
err0
errOAAI
errPowles, Thomas; Park, Se Hoon; Gurney, Howard; Loriot, Yohann; Sridhar, Srikala S.; Bellmunt, Joaquim; di Pietro, Alessandra; Grivas, Petros
errShare
errSave
Perceived cognitive impairment and occupational functioning in prostate cancer survivors: an exploratory cross-sectional analysis
err2025-01-15
err0
errOAAI
errPembroke, Lorna; Sherman, Kerry A.; Dhillon, Haryana M.; Francis, Heather; Gillatt, David; Gurney, Howard
errShare
errSave
Randomized phase II dose comparison LITESPARK-013 study of belzutifan in patients with advanced clear cell renal cell carcinoma
err2024-12-01
err0
PREAI
errAgarwal, N.; Brugarolas, J.; Ghatalia, P.; George, S.; Haanen, J. B.; Gurney, H.; Ravilla, R.; van der Veldt, A.; Beuselinck, B.; Pokataev, I.; Suelmann, B. B. M.; Tuthill, M. H.; Vaena, D.; Zagouri, F.; Wu, J.; Perini, R. F.; Liu, Y.; Merchan, J.; Atkins, M. B.
errShare
errSave
Nivolumab plus relatlimab and nivolumab plus ipilimumab for patients with advanced renal cell carcinoma: results from the open-label, randomised, phase II FRACTION-RCC trial
err2024-12-01
err0
PREAI
errChoueiri, T. K.; Kuzel, T. M.; Tykodi, S. S.; Verzoni, E.; Kluger, H.; Nair, S.; Perets, R.; George, S.; Gurney, H.; Pachynski, R. K.; Folefac, E.; Castonguay, V.; Lee, C. -h.; Vaishampayan, U.; Miller Jr, W. H.; Bhagavatheeswaran, P.; Wang, Y.; Gupta, S.; Desilva, H.; Lee, C. -w.; Escudier, B.; Motzer, R. J.
errShare
errSave
Biomarker analyses from the phase III randomized CLEAR trial: lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinoma
err2024-12-01
err2
errOAAI
errMotzer, R. J.; Porta, C.; Eto, M.; Hutson, T. E.; Rha, S. Y.; Merchan, J. R.; Winquist, E.; Gurney, H.; Gruenwald, V.; George, S.; Markensohn, J.; Burgents, J. E.; Cristescu, R.; Sachdev, P.; Narita, Y.; Huang, J.; Zhao, Z.; Okpara, C. E.; Minoshima, Y.; Choueiri, T. K.
errShare
errSave